The Conversation (0)
Lexaria Bioscience (CSE:LXX,OTCQB:LXRP) was featured in a NetworkNewsWire article regarding merger and acquisition activity in the cannabis industry.
Lexaria Bioscience (CSE:LXX,OTCQB:LXRP) was featured in a NetworkNewsWire article regarding merger and acquisition activity in the cannabis industry. The article positions Lexaria as a potential target for such activity due to its “proprietary technology for improved taste, rapidity and delivery of bioactive compounds, including cannabinoids.”
According to the publication, additional aspects that make the company a compelling target are its patented DehydraTECH drug delivery platform, its current portfolio of 19 international patent applications, its US patent allowance and its focus in the cannabis market.
To read the full article, click here.
Click here to connect with Lexaria Bioscience (CSE:LXX,OTCQB:LXRP) for an Investor Presentation
